Cargando…

Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients

Coronavirus disease 2019 (COVID-19) is a global pandemic that has caused more than 600 million cases and over six million deaths worldwide. Despite the availability of vaccination, COVID-19 cases continue to grow making pharmacological interventions essential. Remdesivir (RDV) is an FDA-approved ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Kaiyan, Stern, Sydney, Heil, Emily L., Li, Linhao, Khairi, Rula, Heyward, Scott, Wang, Hongbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949788/ https://www.ncbi.nlm.nih.gov/pubmed/36809346 http://dx.doi.org/10.1097/HC9.0000000000000034

Ejemplares similares

Transcriptional Regulation of CYP2B6 Expression by Hepatocyte Nuclear Factor 3β in Human Liver Cells
por: Li, Linhao, et al.
Publicado: (2016)

Phenobarbital Induces SLC13A5 Expression through Activation of PXR but Not CAR in Human Primary Hepatocytes
por: Li, Zhihui, et al.
Publicado: (2021)

55484 Dual activation of CAR and Nrf2 improves the efficacy: toxicity ratio of cyclophosphamide and doxorubicin-based treatment of TNBC
por: Stern, Sydney, et al.
Publicado: (2021)

Dexamethasone/propofol/remdesivir: Various toxicities: case report
Publicado: (2021)

Dexamethasone/remdesivir/tocilizumab: Various toxicities: case report
Publicado: (2022)

Micropatterned primary hepatocyte co-culture (HEPATOPAC) for fatty liver disease modeling and drug screening
por: Cottier, Karissa E., et al.
Publicado: (2023)

Dexamethasone/remdesivir: Acute pancreatitis: case report
Publicado: (2022)

The Goldilocks Time for Remdesivir — Is Any Indication Just Right?
por: Heil, Emily L., et al.
Publicado: (2021)

Antibacterials/dexamethasone/remdesivir: Lack of efficacy: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy: case report
Publicado: (2022)

Fewer COVID‐19 Neurological Complications with Dexamethasone and Remdesivir
por: Grundmann, Alexander, et al.
Publicado: (2022)

Dexamethasone/remdesivir: Lack of efficacy and drug withdrawal: case report
Publicado: (2022)

Quantitative High-Throughput Identification of Drugs as Modulators of Human Constitutive Androstane Receptor
por: Lynch, Caitlin, et al.
Publicado: (2015)

Dexamethasone/remdesivir: Derangement of liver function tests, pneumocystis pneumonia and off-label use: case report
Publicado: (2022)

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa
por: Jo, Youngji, et al.
Publicado: (2021)

Dexamethasone/remdesivir: Lack of efficacy and off-label use: case report
Publicado: (2021)

Dexamethasone/remdesivir: Lack of efficacy and off label use: case report
Publicado: (2021)

Dexamethasone/remdesivir: Lack of efficacy and off-label use: case report
Publicado: (2021)

Dexamethasone/remdesivir: Lack of efficacy and off-label use: case report
Publicado: (2022)

Dexamethasone/remdesivir: Lack of efficacy and off-label use: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Methaemoglobinaemia and off-label use: case report
Publicado: (2021)

REMDESIVIR-ASSOCIATED ASYMPTOMATIC BRADYCARDIA IN AN ICU PATIENT ON DEXAMETHASONE FOR COVID-19
por: HAIDER, MOBEEN, et al.
Publicado: (2022)

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
por: Ngo, Dallis Q., et al.
Publicado: (2022)

THE EFFICACY OF REMDESIVIR WITH DEXAMETHASONE VS. DEXAMETHASONE ALONE IN ADULTS HOSPITALIZED WITH COVID-19: A RETROSPECTIVE COHORT STUDY
por: AL-MISTAREHI, ABDEL-HAMEED, et al.
Publicado: (2022)

Cisatracurium besilate/dexamethasone/remdesivir: Malignant hyperthermia and lack of efficacy: case report
Publicado: (2021)

Apixaban/dexamethasone/remdesivir: Off-label use and lack of efficacy: case report
Publicado: (2022)

Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
por: Yoon, Jin Gu, et al.
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy and off label use: case report
Publicado: (2021)

A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone
por: Bhagavan, Sachin M., et al.
Publicado: (2021)

Dexamethasone/remdesivir/tocilizumab: Off-label use and lack of efficacy: case report
Publicado: (2022)

Dexamethasone/methylprednisolone/remdesivir: Off-label use and lack of efficacy: case report
Publicado: (2021)

Sex Differences in Liver Toxicity—Do Female and Male Human Primary Hepatocytes React Differently to Toxicants In Vitro?
por: Mennecozzi, Milena, et al.
Publicado: (2015)

Remdesivir: Various toxicities: 4 case reports
Publicado: (2020)

Remdesivir: Various toxicities: 4 case reports
Publicado: (2020)

Remdesivir: various toxicities: 7 case reports
Publicado: (2021)

Remdesivir: Multiple toxicities: 2 case reports
Publicado: (2021)

Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
por: Izumo, Takehiro, et al.
Publicado: (2021)

Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study
por: Gressens, Simon B., et al.
Publicado: (2022)

Aciclovir/dexamethasone/remdesivir: Lack of efficacy following off-label use: case report
Publicado: (2022)

Dexamethasone/enoxaparin-sodium/remdesivir: Lack of efficacy and off label use: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gv5pj3r7dihbovfpfksdjaucgc